Nasdaq · Healthcare
uniQure N.V. (QURE)
As-reported financials and recent SEC filings for uniQure N.V., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$16.1M
Net income
$-199.0M
Net margin
—
Diluted EPS
$-3.46
ROE
-100.0%
P/E (TTM)
—
Market cap
—
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2025 | FY2025 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $16.1M | $27.1M | $15.8M | $106.5M | $524.0M |
| Gross profit | $14.4M | — | — | — | — |
| Operating income | $-185.3M | $-184.3M | $-282.9M | $-143.2M | $310.6M |
| Net income | $-199.0M | $-239.6M | $-308.5M | $-126.8M | $329.6M |
| Diluted EPS | $-3.46 | $-4.92 | $-6.47 | $-2.71 | $7.04 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →1442026-06-30
View on EDGAR →1442026-06-30
View on EDGAR →42026-06-30
View on EDGAR →1442026-06-26
View on EDGAR →42026-06-26
View on EDGAR →Largest Healthcare peers
Go deeper on QURE
Search uniQure N.V.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.